{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 67 of 169', '10.2.3 Medical history', 'Relevant past and concurrent medical history must be recorded and includes:', 'Skin disease history: all past and current skin disease history including:', 'Alopecia', 'Vitiligo', 'Herpes simplex', 'Atopy history:', 'Duration of AD in years', 'Previous AD treatments', 'Asthma', 'Food allergy', 'Hay fever', 'Allergic conjunctivitis', 'Atopic keratoconjunctivitis', 'Eczema herpeticum', 'Other medical and surgical history including concurrent diagnoses.', 'Relevant medical history includes also diseases which are specifically listed as exclusion', 'criteria and diseases for which specific treatments are listed as exclusion criteria.', '10.2.4 Height and weight', \"The subject's height must be measured (without shoes) and weight must be determined (in\", 'indoor clothing and without shoes).', '10.2.5 Body surface area involvement', 'The total BSA affected by AD will be assessed by the investigator for each section of the body', 'and will be reported as a percentage of all major body sections combined. The following body', 'regions will be assessed (brackets show the highest possible score for each region): head and', 'neck (9%), anterior trunk (18%), back (18%), upper limbs (18%), lower limbs (36%), and', 'genitals (1%). The total BSA score will be assessed according to the SoP (Section 4).', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 68 of 169', '10.3 Efficacy assessments', '10.3.1 Investigator assessments', \"10.3.1.1 Investigator's Global Assessment\", \"The IGA is an instrument used in clinical trials to rate the severity of the subject's global AD\", 'and is based on a 5-point scale ranging from 0 (clear) to 4 (severe) (Panel 10). The IGA score', 'will be assessed according to the SoP (Section 4). The assessment will be based on the', 'condition of the disease at the time of evaluation and not in relation to the condition at a', 'previous visit. Whenever possible, the IGA should be assessed by the same investigator at', 'each visit to reduce inter-rater variability.', \"Panel 10 Investigator's Global Assessment\", 'Score', 'Disease severity', 'Standard IGA scale', 'IGA morphological descriptors', '0', 'Clear', 'No inflammatory signs of', 'No erythema and no elevation', 'atopic dermatitis', '(papulation/infiltration).', 'Just perceptible erythema, and', 'Barely perceptible erythema', 'just perceptible', 'and/or minimal lesion elevation', '1', 'Almost clear', 'papulation/infiltration', '(papulation/infiltration) that is not', 'widespread.', 'Mild erythema and mild', 'Visibly detectable, light pink', '2', 'Mild disease', 'papulation/infiltration', 'erythema and very slight elevation', '(papulation/infiltration)', 'Moderate erythema and', 'Dull red, clearly distinguishable', 'moderate', '3', 'Moderate disease', 'erythema and clearly perceptible', 'papulation/infiltration', 'but not extensive elevation', '(papulation/infiltration).', 'Severe erythema and severe', 'Deep/dark red erythema, marked', '4', 'Severe disease', 'papulation/infiltration', 'and extensive elevation', '(papulation/infiltration).', '10.3.1.2 Eczema Area and Severity Index', 'The EASI is a validated measure used in clinical practice and clinical trials to assess the', 'severity and extent of AD (19). The EASI score will be assessed according to the SoP', '(Section 4). The assessment will be based on the condition of the disease at the time of', 'evaluation and not in relation to the condition at a previous visit. Whenever possible, the', 'EASI should be assessed by the same investigator at each visit to reduce inter-rater variability.', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 69 of 169', 'The EASI is a composite index with scores ranging from 0 to 72, with higher values', 'indicating more severe and/or more extensive condition. The index will be calculated as', 'shown in Panel 11. Briefly, the investigator will assess the severity of 4 AD disease', 'characteristics (erythema, induration/papulation, excoriation, and lichenification) on the', '4 body regions (head/neck, trunk, upper extremities, lower extremities); severity will be', 'assessed according to the scale shown in Panel 12. For each body region, a severity sum score', 'will be calculated which will be multiplied by an area score (Panel 12) and by a weighting', 'factor. The EASI score equals the sum of the scores obtained for each body region (Panel 11).', 'Panel 11 Calculation of the Eczema Area and Severity Index', 'Body region', 'Head/neck', '(SS +', 'SS +', 'SS +', 'SS )', 'x AS', 'x 0.1', 'Trunk', '(SS +', 'SS +', 'SS +', 'SS )', 'X AS', 'X 0.3', 'Upper extremities', '(SS +', 'SS +', 'SS +', 'SS )', 'x AS', 'X 0.2', 'Lower extremities', '( SS +', 'SS +', 'SS +', 'SS )', 'X AS', 'X 0.4', 'The EASI score is the sum of the 4 body region scores', '(range 0-72)', 'AS, area score; EASI, Eczema Area and Severity Index; SS, severity score. Modified from (28).', 'Panel 12 EASI severity score scale and area score scale', 'Severity score scale', 'Area score scale', '0', 'None/absent', '0', '0% affected area', '1', 'Mild', '1', '1% to 9% affected area', '2', 'Moderate', '2', '10% to 29% affected area', '3', 'Severe', '3', '30% to 49% affected area', 'Half-points (0.5; 1.5; 2.5) may also be', '4', '50% to 69% affected area', 'used.', '5', '70% to 89% affected area', '6', '90% to 100% affected area', 'EASI, Eczema Area and Severity Index.', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}